News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Top NPS Pharmaceuticals, Inc. (NPSP) Exec's View On The Megadeal Fallout For Biotechs



5/8/2014 6:50:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Sometime soon, it’s entirely possible that Pfizer will buy AstraZeneca for a price that would exceed the gross national product of all but about 50 countries worldwide. Should that happen, a long, complicated process will unfold. Pfizer (NYSE: PFE) will talk about bringing together two titans with franchises in big fields like oncology, inflammation, and cardiovascular disease, while its financial people tout massive tax savings. Shareholders of AstraZeneca (NYSE: AZN) will walk away with a lot of extra cash and perhaps stock.

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy


comments powered by Disqus
Xconomy
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES